M. L. Méndez-Pérez

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Paricalcitol, a selective vitamin D receptor (VDR) activator used for treatment of secondary hyperparathyroidism in chronic kidney disease (CKD), has been associated with survival advantages, suggesting that this drug, beyond its ability to suppress parathyroid hormone, may have additional beneficial actions. In this prospective, nonrandomised, open-label,(More)
  • 1